Study #2024-1865
A phase 3, randomized, double-blind, placebo-controlled study of optune (TTFields, 200 kHz) concomitant with maintenance temozolomide and pembrolizumab versus optune concomitant with maintenance temozolomide and placebo for the treatment of newly diagnosed glioblastoma (EF-41/KEYNOTE D58)
MD Anderson Study Status
Enrolling
Treatment Agent
Temozolomide, Pembrolizumab, Placebo
Description
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune? (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune? together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma
Study phase:
Phase III
Physician name:
Chirag Patel
Department:
Neuro-Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?